Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema
about
Intravitreal steroids for macular edema in diabetesClinical trials on corticosteroids for diabetic macular edemaCurrent treatment approaches in diabetic macular edema.Pharmacokinetics and retinal toxicity of various doses of intravitreal triamcinolone acetonide in rabbits.Behavior of intraocular pressure after intravitreal injection of triamcinolone acetonide among egyptians.Current treatments in diabetic macular oedema: systematic review and meta-analysisImpact on intraocular pressure after 20-mg decanted triamcinolone acetonide (kenalog) injection when using prophylactic antiglaucoma therapy.Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy.A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema.Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases.Dose dependent effects of intravitreal triamcinolone acetonide on diffuse diabetic macular edema.Diabetic macular edema: what is focal and what is diffuse?Diabetic Retinopathy Clinical Practice Guidelines: Customized for Iranian Population.Triamcinolone and bevacizumab as adjunctive therapies to panretinal photocoagulation for proliferative diabetic retinopathyRedefining tissue engineering for nanomedicine in ophthalmology.Drug safety evaluation of intravitreal triamcinolone acetonide.Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells.Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections.The problem of pressure elevation associated with intravitreal triamcinolone.Development of biodegradable controlled release scleral systems of triamcinolone acetonide.
P2860
Q24242456-F7A61F91-DDAC-40FD-9628-E0F88EA3F8C6Q31146864-31AB2BDB-A00A-4530-83B7-04B99D3B9F01Q33279749-CF84C419-011C-4BBB-9622-AD8F2A489E77Q33614276-0751F908-A1B2-4A65-B883-8105EA25752BQ33939208-5872DEF9-F7E0-49B2-A403-5D9D6AE268DBQ34606190-5D3F2EE2-A9B9-4F6D-9271-CDE5D67CE581Q34771834-B7DF37D8-AFCF-4B5A-B276-60A12CE9032DQ35688128-09409C68-D2A6-4E57-A3BD-4C1937C05FC3Q35762992-82A3EE20-3DF2-4DDA-A6BB-DC41FFE4D184Q36737173-D3163B45-5A8D-4235-A8A1-BB1D1ADC8FC0Q37222318-4403DD9C-53C6-4313-B890-F0FCB01BA1D6Q37261743-C0CEB898-F0FE-4FD1-B789-1D86CF9B9505Q37477129-BC192A39-5B02-4907-B6BB-E1C940096125Q37550878-B9172CBA-5B02-4100-A640-061150AF2831Q37782373-8AEBFBA0-09FE-416D-B1EC-6CB0CCC24B75Q37953969-15CA3755-B5E6-4E79-AAAF-6F76FB56FEC4Q42563270-2A9A6E4A-4158-4B89-8C79-329E26BC0F04Q42634677-242DC7ED-4B5D-4D21-8D2B-5D52F1249EB7Q42841761-DCA62393-0095-4DDD-A5B3-ABD5853156EAQ42881021-98D4DD41-3A58-414D-B363-7F1493838F33
P2860
Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Dosage dependency of intravitr ...... nt for diabetic macular oedema
@en
Dosage dependency of intravitr ...... nt for diabetic macular oedema
@nl
type
label
Dosage dependency of intravitr ...... nt for diabetic macular oedema
@en
Dosage dependency of intravitr ...... nt for diabetic macular oedema
@nl
prefLabel
Dosage dependency of intravitr ...... nt for diabetic macular oedema
@en
Dosage dependency of intravitr ...... nt for diabetic macular oedema
@nl
P2093
P2860
P356
P1476
Dosage dependency of intravitr ...... nt for diabetic macular oedema
@en
P2093
C Papoulis
P Schmitz-Valckenberg
U H M Spandau
P2860
P304
P356
10.1136/BJO.2004.062596
P407
P577
2005-08-01T00:00:00Z